Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03172936 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT03172936 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 106 participants.
The verdict
NCT03172936, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
Interventions
- BIOLOGICAL PDR001
- DRUG MIW815
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2017-09-08 |
| Est. Completion | 2020-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03172936
The ClinicalTrials.gov registry entry for NCT03172936 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT03172936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03172936 about?
NCT03172936 is a clinical study titled "Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas". The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
What is the current status of trial NCT03172936?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2017-09-08. Estimated completion is 2020-12-18.
What interventions are being tested in trial NCT03172936?
The interventions under investigation include: PDR001 (BIOLOGICAL), MIW815 (DRUG).
Who is sponsoring clinical trial NCT03172936?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.